inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe
Company profile
Ticker
IFRX
Exchange
Website
CEO
Niels Christoph Riedemann
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Fireman B.V.
SEC CIK
IFRX stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
25 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Corporate Presentation March 2024
21 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
21 Mar 24
6-K
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25 Jan 24
6-K
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4 Jan 24
6-K
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
6 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
11 Sep 23
Latest ownership filings
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
24 Apr 23
SC 13G
TANG CAPITAL PARTNERS LP
17 Apr 23
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 22
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
8 Mar 21
SC 13G
GREAT POINT PARTNERS LLC
8 Mar 21
SC 13G/A
BAKER BROS. ADVISORS LP
16 Feb 21
SC 13D
Beneficial ownership report
18 Feb 20
SC 13D
InflaRx N.V.
18 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
36.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 18 |
Closed positions | 4 |
Increased positions | 10 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 81.72 bn |
Total shares | 21.45 mm |
Total puts | 32.10 k |
Total calls | 125.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Suvretta Capital Management | 5.73 mm | $25.57 bn |
Tang Capital Partners | 3.00 mm | $0.00 |
Tang Capital Management | 2.90 mm | $12.93 bn |
683 Capital Management | 2.00 mm | $8.92 bn |
Eversept Partners | 1.92 mm | $8.54 bn |
Point72 Asset Management | 1.91 mm | $8.53 bn |
MS Morgan Stanley | 629.92 k | $2.81 bn |
Woodline Partners | 492.60 k | $2.20 bn |
Millennium Management | 371.11 k | $1.66 bn |
Schonfeld Strategic Advisors | 368.99 k | $1.65 bn |